 Home > Biochemistry News > Biotechnology News > Painless patients double oral multi-mechanism migraine therapy within 2 hours, expected to be approved next year

Painless patients double oral multi-mechanism migraine therapy within 2 hours, expected to be approved next year

 Last Update: 2021-09-18
 Source: Internet
 Author: User

Tags

blepharospasm treatment

swift application

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 14, 2021, Axsome Therapeutics announced that the US FDA has accepted the New Drug Application (NDA) for the compound migraine therapy AXS-07 with multiple mechanisms of action for the acute treatment of migraine.

Migraine is a neurological disease characterized by severe headaches.

AXS-07 is a new, oral, fast-absorbed, multi-mechanism drug under development for the acute treatment of migraine.

This application is based on the positive results obtained from two randomized double-blind phase 3 controlled clinical trials MOMENTUM and INTERCEPT

▲AXS-07 reached the common primary endpoint of the INTERCEPT trial (Image source: Axsome official website)

Reference materials:

[1] Axsome Therapeutics Announces Fda Acceptance Of New Drug Application For Axs-07 For The Acute Treatment Of Migraine.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express delivery doubles painless patients within 2 hours, oral multi-mechanism migraine therapy is expected to be approved next year

10-01

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Painless patients double oral multi-mechanism migraine therapy within 2 hours, expected to be approved next year

Related Articles

Express delivery doubles painless patients within 2 hours, oral multi-mechanism migraine therapy is expected to be approved next year